Marinus Pharmaceuticals Stock Performance
| MRNS Stock | USD 0.32 0.01 3.03% |
The company secures a Beta (Market Risk) of 1.63, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Marinus Pharmaceuticals will likely underperform. At this point, Marinus Pharmaceuticals has a negative expected return of -0.69%. Please make sure to verify Marinus Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Marinus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Marinus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:4 | Dividend Date 2020-09-23 | Last Split Date 2020-09-23 |
1 | Marinus Pharmaceuticals Market Outperform Rating Reiterated at JMP Securities | 09/26/2024 |
2 | Disposition of 1660 shares by Mayleben Timothy M of Marinus Pharmaceuticals subject to Rule 16b-3 | 10/10/2024 |
3 | Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY Titration Regimens | 10/15/2024 |
4 | Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment | 10/18/2024 |
5 | Marinus tanks after late stage trial for treatment of seizures fails to meet main goal | 10/24/2024 |
6 | GSK invests 800M in manufacturing Amgen sets small discount for Eylea biosimilar | 10/25/2024 |
7 | Marinus Pharma earnings missed by 0.01, revenue fell short of estimates | 11/12/2024 |
8 | US1.86 Thats What Analysts Think Marinus Pharmaceuticals, Inc. Is Worth After Its Latest Results | 11/15/2024 |
| Begin Period Cash Flow | 240.6 M |
Marinus |
Marinus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 143.00 in Marinus Pharmaceuticals on August 31, 2024 and sell it today you would lose (111.00) from holding Marinus Pharmaceuticals or give up 77.62% of portfolio value over 90 days. Marinus Pharmaceuticals is currently does not generate positive expected returns and assumes 12.7243% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Marinus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Marinus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marinus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Marinus Pharmaceuticals, and traders can use it to determine the average amount a Marinus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0544
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRNS |
Estimated Market Risk
| 12.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.69 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Marinus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marinus Pharmaceuticals by adding Marinus Pharmaceuticals to a well-diversified portfolio.
Marinus Pharmaceuticals Fundamentals Growth
Marinus Stock prices reflect investors' perceptions of the future prospects and financial health of Marinus Pharmaceuticals, and Marinus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marinus Stock performance.
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (3.76) % | ||||
| Current Valuation | 31.73 M | ||||
| Shares Outstanding | 55.19 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 30.99 M | ||||
| Gross Profit | (55.94 M) | ||||
| EBITDA | (125.5 M) | ||||
| Net Income | (141.41 M) | ||||
| Cash And Equivalents | 168.25 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 110.36 M | ||||
| Debt To Equity | 0.88 % | ||||
| Current Ratio | 8.41 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (118 M) | ||||
| Earnings Per Share | (2.47) X | ||||
| Market Capitalization | 17.92 M | ||||
| Total Asset | 170.91 M | ||||
| Retained Earnings | (571.93 M) | ||||
| Working Capital | 124.62 M | ||||
| Current Asset | 57.77 M | ||||
| Current Liabilities | 7.43 M | ||||
About Marinus Pharmaceuticals Performance
Assessing Marinus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Marinus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Marinus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 455.40 | 478.17 | |
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (1.01) | (1.06) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (8.43) | (8.01) |
Things to note about Marinus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Marinus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Marinus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Marinus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Marinus Pharmaceuticals has high historical volatility and very poor performance | |
| Marinus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Marinus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 30.99 M. Net Loss for the year was (141.41 M) with loss before overhead, payroll, taxes, and interest of (55.94 M). | |
| Marinus Pharmaceuticals currently holds about 168.25 M in cash with (118 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Marinus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: US1.86 Thats What Analysts Think Marinus Pharmaceuticals, Inc. Is Worth After Its Latest Results |
- Analyzing Marinus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marinus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Marinus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Marinus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marinus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Marinus Pharmaceuticals' stock. These opinions can provide insight into Marinus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.